HRP20110654T1 - Dimeri derivata artemizinina, njihovo dobivanje i upotreba u terapiji - Google Patents
Dimeri derivata artemizinina, njihovo dobivanje i upotreba u terapiji Download PDFInfo
- Publication number
- HRP20110654T1 HRP20110654T1 HR20110654T HRP20110654T HRP20110654T1 HR P20110654 T1 HRP20110654 T1 HR P20110654T1 HR 20110654 T HR20110654 T HR 20110654T HR P20110654 T HRP20110654 T HR P20110654T HR P20110654 T1 HRP20110654 T1 HR P20110654T1
- Authority
- HR
- Croatia
- Prior art keywords
- epoxy
- decahydro
- trimethyl
- trifluoromethyl
- image
- Prior art date
Links
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title 1
- 239000000539 dimer Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000002253 acid Substances 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000001093 anti-cancer Effects 0.000 claims abstract 2
- 150000002118 epoxides Chemical class 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims 17
- -1 2,1-ethanediyloxy Chemical group 0.000 claims 7
- 239000004593 Epoxy Substances 0.000 claims 6
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/04—Seven-membered rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/04—Seven-membered rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
- C07D323/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Abstract
Antikancerozni produkt formule (I): naznačen time što: a) A je dvovalentna skupina, koju se bira između -S-, -SO-, -SO2-, -NH-, -N(CH2-C(O)O-CH2-CH3)- ili -N(CH2-COOH)-, epoksida, (C1-C6)alkilena, -NHCO- ili 1,2,3-triazola; b) X1 i X2 su isti i jesu O; c) n1 i n2 su isti ili različit i imaju vrijednost 1, 2, 3 ili 4; u obliku baze ili adicijske soli s kiselinom, te u obliku hidrata ili solvata. Patent sadrži još 11 patentnih zahtjeva.
Claims (12)
1. Antikancerozni produkt formule (I):
[image]
naznačen time što:
a) A je dvovalentna skupina, koju se bira između -S-, -SO-, -SO2-, -NH-, -N(CH2-C(O)O-CH2-CH3)- ili -N(CH2-COOH)-, epoksida, (C1-C6)alkilena, -NHCO- ili 1,2,3-triazola;
b) X1 i X2 su isti i jesu O;
c) n1 i n2 su isti ili različit i imaju vrijednost 1, 2, 3 ili 4;
u obliku baze ili adicijske soli s kiselinom, te u obliku hidrata ili solvata.
2. Produkt u skladu s patentnim zahtjevom 1, naznačen time što n1 i n2 su isti i imaju vrijednost 2, 3 ili 4.
3. Produkt u skladu s patentnim zahtjevom 1, naznačen time što A se bira između -NH-, -N(CH2-C(O)O-CH2-CH3)- ili -N(CH2-COOH)-, te što su n1 i n2 isti i imaju vrijednost 2.
4. Produkt u skladu s patentnim zahtjevom 1, naznačen time što A se bira između (C1-C6)alkenilena ili epoksida, te što su n1 i n2 isti i imaju vrijednost 1.
5. Produkt u skladu s patentnim zahtjevom 1, naznačen time što A se bira između -NHCO- ili -1,2,3-triazola, te što su n1 i n2 različiti i neovisno imaju vrijednost 1 ili 2.
6. Produkt u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što produkt je
• u nekiralnom obliku, ili
• u racemičnom obliku, ili
• u obliku obogaćenom jednim stereoizomerom, ili
• u obliku obogaćenom jednim enantiomerom;
te time što je izborno u obliku soli.
7. Produkt u skladu s patentnim zahtjevom 1, naznačen time što ga se bira sa sljedećeg spiska, kojeg čine:
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[tiobis(2,1-etandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfinilbis(2,1-etandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfonilbis(2,1-etandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[tiobis(3,1-propandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfinilbis(3,1-propandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfonilbis(3,1-propandiiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[tiobis(4,1-butanediiloksi)]bis[dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin;
– 2-[[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin-10-il]oksi]-N-[2-[[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-dekahidro-3,6,9-trimetil-10-(trifluormetil)-3,12-epoksi-12H-pirano[4,3-j]-1,2-benzodioksepin-10-il]oksi]etil]-N-metiletanamin;
– 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}-N-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)etanamin;
– etil-N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)glicinat;
– N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)glicin;
– 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}-N-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)acetamid;
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2E)-but-2-en-1,4-diilbis(oksi)]bis[3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen];
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2Z)-but-2-en-1,4-diilbis(oksi)]bis[3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen];
– (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2R,3R)-oksiran-2,3-diilbis(metilenoksi)]bis[3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen];
– (1-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)-4-({[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}metil)-1H-1,2,3-triazol;
– 1-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)-5-({[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimetil-10-(trifluormetil)dekahidro-3,12-epoksi[1,2]dioksepino[4,3-i]izokromen-10-il]oksi}etil)-1H-1,2,3-triazol.
8. Produkt u skladu s patentnim zahtjevom 1, naznačen time što ga se bira sa sljedećeg spiska, kojeg čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
9. Produkt u skladu s patentnim zahtjevom 8, naznačen time što produkt je
• u nekiralnom obliku, ili
• u racemičnom obliku, ili
• u obliku obogaćenom jednim stereoizomerom, ili
• u obliku obogaćenom jednim enantiomerom;
te time što je izborno u obliku soli.
10. Farmaceutski pripravak, naznačen time što sadrži produkt u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili adicijsku sol ovog produkta s farmaceutski prihvatljivom kiselinom, ili hidrat ili solvat ovog produkta.
11. Medikament, naznačen time što sadrži produkt u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili adicijsku sol ovog produkta s farmaceutski prihvatljivom kiselinom, ili hidrat ili solvat ovog produkta.
12. Međuprodukt formule (II):
[image]
naznačen time što n ima vrijednost 1, 2, 3 ili 4, a G predstavlja atom broma ili skupinu -N3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0603209A FR2899586B1 (fr) | 2006-04-11 | 2006-04-11 | Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique |
| PCT/FR2007/000585 WO2007116135A1 (fr) | 2006-04-11 | 2007-04-06 | Dimeres de derives d'artemisinine, leur préparation et leur application en thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110654T1 true HRP20110654T1 (hr) | 2011-10-31 |
Family
ID=37429238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110654T HRP20110654T1 (hr) | 2006-04-11 | 2011-09-13 | Dimeri derivata artemizinina, njihovo dobivanje i upotreba u terapiji |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US8314142B2 (hr) |
| EP (1) | EP2007769B1 (hr) |
| JP (1) | JP5265518B2 (hr) |
| KR (1) | KR101357523B1 (hr) |
| CN (1) | CN101421276B (hr) |
| AR (1) | AR060400A1 (hr) |
| AT (1) | ATE512970T1 (hr) |
| AU (1) | AU2007235813B2 (hr) |
| BR (1) | BRPI0710152A2 (hr) |
| CA (1) | CA2641138C (hr) |
| CR (1) | CR10247A (hr) |
| CY (1) | CY1111833T1 (hr) |
| DK (1) | DK2007769T3 (hr) |
| EA (1) | EA015607B1 (hr) |
| EC (1) | ECSP088792A (hr) |
| ES (1) | ES2367715T3 (hr) |
| FR (1) | FR2899586B1 (hr) |
| GT (1) | GT200800206A (hr) |
| HK (1) | HK1131779A1 (hr) |
| HN (1) | HN2008001521A (hr) |
| HR (1) | HRP20110654T1 (hr) |
| IL (1) | IL194655A0 (hr) |
| JO (1) | JO2721B1 (hr) |
| MA (1) | MA30410B1 (hr) |
| ME (1) | ME00094B (hr) |
| MX (1) | MX2008012732A (hr) |
| MY (1) | MY154970A (hr) |
| NO (1) | NO20084352L (hr) |
| NZ (1) | NZ571342A (hr) |
| PE (1) | PE20080055A1 (hr) |
| PL (1) | PL2007769T3 (hr) |
| PT (1) | PT2007769E (hr) |
| RS (1) | RS51952B (hr) |
| SI (1) | SI2007769T1 (hr) |
| TN (1) | TNSN08321A1 (hr) |
| TW (1) | TWI423979B (hr) |
| UA (1) | UA94744C2 (hr) |
| UY (1) | UY30276A1 (hr) |
| WO (1) | WO2007116135A1 (hr) |
| ZA (1) | ZA200808025B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2925495B1 (fr) * | 2007-12-21 | 2010-09-10 | Pf Medicament | Derives dimeriques d'artemisinine et application en therapie anticancereuse |
| FR2934593B1 (fr) * | 2008-07-29 | 2010-09-10 | Pf Medicament | Derives dimeriques d'artemisinine et application en therapie anticancereuse |
| US8883765B2 (en) * | 2009-12-08 | 2014-11-11 | The John Hopkins University | Anti-cytomegalovirus activity of artemisinin-derived dimers |
| US8815942B2 (en) | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
| CN102010422B (zh) * | 2010-11-23 | 2014-11-26 | 沈阳药科大学 | 含有胍基的青蒿素类衍生物及其应用 |
| CN102614168A (zh) * | 2011-01-31 | 2012-08-01 | 上海交通大学医学院附属瑞金医院 | 一种青蒿素衍生物及其药用盐的应用 |
| WO2012111025A2 (en) * | 2011-02-14 | 2012-08-23 | Council Of Scientific & Industrial Research | 1,2,3-triazole containing artemisinin compounds and process for preparation thereof |
| WO2014023081A1 (zh) * | 2012-08-07 | 2014-02-13 | 中国科学院上海生命科学研究院 | 青嵩素衍生物及其制法和应用 |
| CN106928274B (zh) * | 2017-02-28 | 2019-09-10 | 东南大学 | 一种双氢青蒿素二倍体衍生物、其药物组合物及应用 |
| CN110240605B (zh) * | 2018-03-08 | 2021-12-31 | 中国科学院上海药物研究所 | 青蒿素二聚物的制备方法 |
| CN109467565B (zh) * | 2018-08-16 | 2020-07-10 | 云白药征武科技(上海)有限公司 | 双氢青蒿素三聚体及其制备方法和应用 |
| US20220175937A1 (en) * | 2019-02-26 | 2022-06-09 | Mahmoud A. Elsohly | Selected artemisinin dimers for the treatment of lashmaniasis |
| CN117285548A (zh) * | 2022-06-16 | 2023-12-26 | 云南苏理生物医药科技有限公司 | 一种含硫类青蒿素二聚体、其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084333C (zh) * | 1998-06-17 | 2002-05-08 | 中国科学院上海药物研究所 | 新的青蒿素化合物,其制备方法以及含有它们的药物组合物 |
| FR2831538B1 (fr) * | 2001-10-26 | 2004-01-16 | Centre Nat Rech Scient | Nouveaux derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme |
| US6790863B2 (en) * | 2002-10-15 | 2004-09-14 | University Of Mississippi | Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| CA2570961C (en) * | 2004-06-21 | 2015-09-01 | University Of Mississippi | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
| CN101125142A (zh) | 2007-07-24 | 2008-02-20 | 北京中医药大学东直门医院 | 青蒿素在制备抗肿瘤多药耐药药物中的应用 |
-
2006
- 2006-04-11 FR FR0603209A patent/FR2899586B1/fr not_active Expired - Fee Related
-
2007
- 2007-04-06 CN CN200780013054XA patent/CN101421276B/zh not_active Expired - Fee Related
- 2007-04-06 SI SI200730713T patent/SI2007769T1/sl unknown
- 2007-04-06 DK DK07731259.3T patent/DK2007769T3/da active
- 2007-04-06 ZA ZA200808025A patent/ZA200808025B/xx unknown
- 2007-04-06 EP EP07731259A patent/EP2007769B1/fr active Active
- 2007-04-06 KR KR1020087024812A patent/KR101357523B1/ko not_active IP Right Cessation
- 2007-04-06 PT PT07731259T patent/PT2007769E/pt unknown
- 2007-04-06 ME MEP-2008-123A patent/ME00094B/me unknown
- 2007-04-06 UA UAA200813044A patent/UA94744C2/ru unknown
- 2007-04-06 JP JP2009504774A patent/JP5265518B2/ja not_active Expired - Fee Related
- 2007-04-06 MX MX2008012732A patent/MX2008012732A/es active IP Right Grant
- 2007-04-06 RS RS20110399A patent/RS51952B/en unknown
- 2007-04-06 PL PL07731259T patent/PL2007769T3/pl unknown
- 2007-04-06 BR BRPI0710152-0A patent/BRPI0710152A2/pt not_active IP Right Cessation
- 2007-04-06 EA EA200870421A patent/EA015607B1/ru not_active IP Right Cessation
- 2007-04-06 NZ NZ571342A patent/NZ571342A/en not_active IP Right Cessation
- 2007-04-06 CA CA2641138A patent/CA2641138C/fr not_active Expired - Fee Related
- 2007-04-06 AT AT07731259T patent/ATE512970T1/de active
- 2007-04-06 AU AU2007235813A patent/AU2007235813B2/en not_active Ceased
- 2007-04-06 ES ES07731259T patent/ES2367715T3/es active Active
- 2007-04-06 MY MYPI20084058A patent/MY154970A/en unknown
- 2007-04-06 WO PCT/FR2007/000585 patent/WO2007116135A1/fr active Application Filing
- 2007-04-09 PE PE2007000422A patent/PE20080055A1/es not_active Application Discontinuation
- 2007-04-10 AR ARP070101497A patent/AR060400A1/es not_active Application Discontinuation
- 2007-04-10 TW TW096112535A patent/TWI423979B/zh not_active IP Right Cessation
- 2007-04-11 UY UY30276A patent/UY30276A1/es not_active Application Discontinuation
- 2007-04-11 JO JO2007131A patent/JO2721B1/en active
-
2008
- 2008-08-07 TN TNP2008000321A patent/TNSN08321A1/en unknown
- 2008-08-26 CR CR10247A patent/CR10247A/es unknown
- 2008-10-02 US US12/244,225 patent/US8314142B2/en not_active Expired - Fee Related
- 2008-10-03 HN HN2008001521A patent/HN2008001521A/es unknown
- 2008-10-06 EC EC2008008792A patent/ECSP088792A/es unknown
- 2008-10-07 IL IL194655A patent/IL194655A0/en unknown
- 2008-10-08 GT GT200800206A patent/GT200800206A/es unknown
- 2008-10-16 NO NO20084352A patent/NO20084352L/no not_active Application Discontinuation
- 2008-11-10 MA MA31376A patent/MA30410B1/fr unknown
-
2009
- 2009-10-21 HK HK09109745.0A patent/HK1131779A1/xx not_active IP Right Cessation
-
2011
- 2011-09-13 HR HR20110654T patent/HRP20110654T1/hr unknown
- 2011-09-15 CY CY20111100886T patent/CY1111833T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110654T1 (hr) | Dimeri derivata artemizinina, njihovo dobivanje i upotreba u terapiji | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| DK2026775T3 (en) | USE OF SYK tyrosine kinase inhibitors for treating cell proliferative DISORDERS | |
| EP2292593A3 (en) | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | |
| US7964738B2 (en) | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | |
| JP5441928B2 (ja) | 一酸化窒素供与化合物 | |
| JP2009504763A5 (hr) | ||
| JP2010505873A5 (ja) | 化合物、会合複合体、及び会合複合体を形成する方法 | |
| JP2010077141A5 (hr) | ||
| EA005817B1 (ru) | Производные гексагидро-7-1h-азепин-2-илгексановой (или гексеновой) кислоты в качестве ингибиторов индуцибельной синтазы оксида азота | |
| JP2002543202A5 (hr) | ||
| SE0302760D0 (sv) | New compounds | |
| JP2004501189A5 (hr) | ||
| MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
| MX2009012041A (es) | Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa. | |
| JP2006504738A5 (hr) | ||
| RU2020119562A (ru) | Хиназолиноновое соединение и его применение | |
| RU2013112807A (ru) | Композиция для доставки активных агентов в желудок | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| WO2003049676A3 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer | |
| JP2019503356A5 (hr) | ||
| RU2506072C2 (ru) | Фармацевтическая композиция, содержащая 11-дезокси-простагландиновое соединение, и способ стабилизации этого соединения | |
| WO2015106283A1 (en) | Antifungal compounds | |
| EA200100597A2 (ru) | Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции | |
| WO2010004579A3 (en) | Orally active curcuminoid compounds |